Updated Jul 29, 7:19 PM · 60 sources analyzed
Key Takeaways
Roche's oral obesity drug RO7795081 completed Phase 2 dose-ranging; no efficacy data released yet, but data readout will benchmark against oral semaglutide.
Genfit's VS-01 Phase 2 (UNVEIL-IT) in acute-on-chronic liver failure was terminated, narrowing an already thin pipeline for the French biotech.
Amgen logged three Phase 3 completions for rocatinlimab in atopic dermatitis; a full data disclosure and BLA filing timeline are the next critical milestones.
🏆 Winner
Amgen — three simultaneous Phase 3 completions for rocatinlimab signal regulatory package assembly in atopic dermatitis is advancing.
📉 Loser
Genfit — termination of the VS-01 UNVEIL-IT Phase 2 in acute-on-chronic liver failure removes a key pipeline asset with no disclosed explanation.
🔭 Watch Next
Akero Therapeutics' Symmetry Phase 2 data in F4 compensated NASH cirrhosis is expected to be presented at AASLD 2026, representing one of the most consequential near-term readouts in liver disease drug development.
Roche's obesity drug RO7795081 completes Phase 2 dose-ranging study
Hoffmann-La Roche completed a randomized, double-blind, placebo-controlled Phase 2 dose-ranging study of RO7795081, an oral small molecule, in adults with obesity or overweight plus at least one weight-related comorbidity. The study, now marked Completed on ClinicalTrials.gov, was designed to evaluate efficacy, tolerability, and safety across multiple doses — but no numerical results have been released publicly. In a crowded oral obesity field where GLP-1 alternatives are under intense scrutiny, any forthcoming data package from Roche will be closely benchmarked against oral semaglutide and other emerging entrants.
ClinicalTrials.gov ↗Hoffmann-La Roche
RO7795081 in Obesity or overweight with weight-related comorbidity
ClinicalTrials.gov registry lists the study (NCT07081958) as Completed. The study was a multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-range-finding design evaluating efficacy, tolerability, and safety of daily oral RO7795081. Full numerical efficacy and safety data have not yet been released.
Why it matters
Registry completion signals Roche is moving through the dose-selection process, but without disclosed efficacy figures, investors cannot assess whether RO7795081 clears the bar set by oral semaglutide in weight reduction. The key question for the investment thesis is whether Roche can show meaningful body weight reduction with an acceptable GI tolerability profile that distinguishes it from existing oral GLP-1 agents.
What to watch
Watch for Roche to present dose-ranging efficacy and safety data at a major metabolic disease conference such as EASD or ObesityWeek, likely in late 2026, which will determine whether the program advances to Phase 3.
Amgen
Rocatinlimab in Moderate-to-severe atopic dermatitis (adolescents)
ClinicalTrials.gov registry lists two Phase 3 rocatinlimab studies as Completed: NCT05633355 (safety and tolerability in adolescents) and NCT05899816 (ROCKET-VOYAGER, vaccine antibody response assessment vs. placebo). A third Phase 3 study, ROCKET-IGNITE (NCT05398445), evaluating monotherapy efficacy and safety, is also listed as Completed. No numerical efficacy or safety results have been publicly disclosed from these registry updates.
Why it matters
Three simultaneous Phase 3 completions in atopic dermatitis suggest Amgen is assembling a regulatory package for rocatinlimab, but the program's investment thesis hinges on durability of response after treatment cessation — a feature Amgen has previously highlighted as a potential differentiator. The vaccine response data from VOYAGER is also a key safety data point that regulators will scrutinize.
What to watch
Watch for Amgen to disclose full Phase 3 efficacy and safety data — particularly ROCKET-IGNITE monotherapy results — at a dermatology congress such as EADV 2026, followed by a BLA submission timeline announcement.
Genfit
VS-01 in Acute-on-chronic liver failure with ascites
ClinicalTrials.gov lists the UNVEIL-IT Phase 2 study (NCT05900050) of VS-01 — an intraperitoneal liposomal formulation — in acute-on-chronic liver failure with ascites as Terminated. No efficacy or safety outcome data have been disclosed alongside the termination notice.
Why it matters
A terminated Phase 2 in a high-mortality indication like acute-on-chronic liver failure is a setback for Genfit, which has been trying to rebuild pipeline credibility after prior liver disease failures. Without a disclosed reason for termination, investors must weigh whether this reflects a business decision, safety signal, or efficacy shortfall — each scenario carries different implications for the company's remaining assets.
What to watch
Watch for Genfit to issue an official statement clarifying the reason for UNVEIL-IT termination and to update investors on the status of its remaining pipeline at the next scheduled earnings or R&D day.
Akero Therapeutics' efruxifermin Phase 2 in compensated NASH cirrhosis (Symmetry) reaches completion
ClinicalTrials.gov lists the Symmetry Phase 2 study (NCT05039450) of efruxifermin (EFX), an FGF21 analogue, in biopsy-proven F4 compensated NASH cirrhosis as Completed; the randomized, double-blind, placebo-controlled trial enrolled cirrhotic patients — a population with very limited treatment options.
Why it matters
Akero is one of the leading independent NASH players, and Symmetry data in F4 cirrhosis — if positive — would differentiate EFX from competitors whose trials focused on F2-F3 fibrosis. The investment thesis for Akero rests heavily on whether EFX can show histological improvement in this harder-to-treat population.
What to watch
Watch for Akero to disclose Symmetry biopsy-confirmed fibrosis improvement rates at The Liver Meeting (AASLD) 2026, which will determine whether a Phase 3 registration trial in compensated cirrhosis is warranted.
ClinicalTrials.gov registry lists the study (NCT07081958) as Completed. The study was a multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-range-finding design evaluating efficacy, tolerability, and safety of daily oral RO7795081. Full numerical efficacy and safety data have not yet been released.
Why it matters
Roche's oral obesity asset joining a field dominated by Novo Nordisk and Eli Lilly creates competitive pressure; data quality and tolerability profile will determine whether this program has differentiated potential.
Analysis
Registry completion signals Roche is moving through the dose-selection process, but without disclosed efficacy figures, investors cannot assess whether RO7795081 clears the bar set by oral semaglutide in weight reduction. The key question for the investment thesis is whether Roche can show meaningful body weight reduction with an acceptable GI tolerability profile that distinguishes it from existing oral GLP-1 agents.
What to watch
Watch for Roche to present dose-ranging efficacy and safety data at a major metabolic disease conference such as EASD or ObesityWeek, likely in late 2026, which will determine whether the program advances to Phase 3.
ClinicalTrials.gov registry lists the Phase 2b CLEAR-AKI study (NCT05996835) as Completed. The study was designed to characterize the dose-response relationship and evaluate safety and efficacy of three different single doses of TIN816 in hospitalized adults with sepsis-associated AKI (acute kidney injury). No efficacy or safety results have been publicly disclosed.
Why it matters
Sepsis-associated AKI remains an area with no approved disease-modifying therapies; a positive dose-response signal for TIN816 would justify Phase 3 investment in a high-unmet-need indication.
Analysis
Completion of a dose-finding Phase 2b positions Novartis to make a go/no-go decision for Phase 3 in sepsis-AKI, but the absence of disclosed data makes it impossible to assess the program's strength. Investors should watch for a data publication or conference presentation that reveals whether TIN816 showed a clean dose-response on renal function endpoints without excessive safety signals.
What to watch
Watch for Novartis to present CLEAR-AKI data at a nephrology or critical care congress such as ASN Kidney Week 2026, where the dose-response signal will determine the Phase 3 design.
ClinicalTrials.gov registry lists two Phase 3 rocatinlimab studies as Completed: NCT05633355 (safety and tolerability in adolescents) and NCT05899816 (ROCKET-VOYAGER, vaccine antibody response assessment vs. placebo). A third Phase 3 study, ROCKET-IGNITE (NCT05398445), evaluating monotherapy efficacy and safety, is also listed as Completed. No numerical efficacy or safety results have been publicly disclosed from these registry updates.
Why it matters
Completion of multiple Phase 3 studies positions Amgen for a potential BLA submission for rocatinlimab in atopic dermatitis, but the competitive landscape — including dupilumab, lebrikizumab, and tralokinumab — demands a compelling differentiation story.
Analysis
Three simultaneous Phase 3 completions in atopic dermatitis suggest Amgen is assembling a regulatory package for rocatinlimab, but the program's investment thesis hinges on durability of response after treatment cessation — a feature Amgen has previously highlighted as a potential differentiator. The vaccine response data from VOYAGER is also a key safety data point that regulators will scrutinize.
What to watch
Watch for Amgen to disclose full Phase 3 efficacy and safety data — particularly ROCKET-IGNITE monotherapy results — at a dermatology congress such as EADV 2026, followed by a BLA submission timeline announcement.
ClinicalTrials.gov lists the Phase 3 study (NCT05198934) comparing sotorasib 240 mg plus panitumumab versus investigator's choice in previously treated KRAS p.G12C-mutated colorectal cancer as Completed. The primary endpoint was progression-free survival (PFS). No updated numerical results from this registry status change have been disclosed.
Why it matters
KRAS p.G12C-targeted therapy in colorectal cancer remains a competitive space with Mirati's adagrasib also pursuing the indication; the sotorasib-panitumumab combination data will inform the standard of care debate for this genetically defined subgroup.
Analysis
The Phase 3 completion in KRAS-mutated CRC is a meaningful step for Amgen's CodeBreaK program, but given that earlier data already supported the combination, the regulatory and commercial question now centers on the magnitude of PFS benefit and whether it translates to an overall survival advantage that could drive label expansion beyond second-line use.
What to watch
Watch for Amgen to present updated overall survival data from this Phase 3 at ESMO 2026 or ASCO GI 2027, and for a potential sNDA (supplemental new drug application) filing for the combination in CRC.
ClinicalTrials.gov lists the UNVEIL-IT Phase 2 study (NCT05900050) of VS-01 — an intraperitoneal liposomal formulation — in acute-on-chronic liver failure with ascites as Terminated. No efficacy or safety outcome data have been disclosed alongside the termination notice.
Why it matters
Termination of UNVEIL-IT removes VS-01 from Genfit's active pipeline and narrows the company's clinical-stage options in liver disease, a field it has invested in heavily following the setback of elafibranor in NASH.
Analysis
A terminated Phase 2 in a high-mortality indication like acute-on-chronic liver failure is a setback for Genfit, which has been trying to rebuild pipeline credibility after prior liver disease failures. Without a disclosed reason for termination, investors must weigh whether this reflects a business decision, safety signal, or efficacy shortfall — each scenario carries different implications for the company's remaining assets.
What to watch
Watch for Genfit to issue an official statement clarifying the reason for UNVEIL-IT termination and to update investors on the status of its remaining pipeline at the next scheduled earnings or R&D day.
Akero Therapeutics' efruxifermin Phase 2 in compensated NASH cirrhosis (Symmetry) reaches completion
ClinicalTrials.gov lists the Symmetry Phase 2 study (NCT05039450) of efruxifermin (EFX), an FGF21 analogue, in biopsy-proven F4 compensated NASH cirrhosis as Completed; the randomized, double-blind, placebo-controlled trial enrolled cirrhotic patients — a population with very limited treatment options.
Why it matters
Efficacy data in compensated cirrhosis from this study will be critical to establishing whether FGF21-pathway agents can reverse or stabilize fibrosis at its most advanced pre-decompensation stage, which would define a new treatment opportunity in NASH.
Analysis
Akero is one of the leading independent NASH players, and Symmetry data in F4 cirrhosis — if positive — would differentiate EFX from competitors whose trials focused on F2-F3 fibrosis. The investment thesis for Akero rests heavily on whether EFX can show histological improvement in this harder-to-treat population.
What to watch
Watch for Akero to disclose Symmetry biopsy-confirmed fibrosis improvement rates at The Liver Meeting (AASLD) 2026, which will determine whether a Phase 3 registration trial in compensated cirrhosis is warranted.
Regeneron's mibavademab Phase 3 switch study in generalized lipodystrophy reaches completion
ClinicalTrials.gov lists a Phase 3 safety study (NCT06548100) of mibavademab — a leptin receptor agonist antibody — in patients with generalized lipodystrophy (GLD) switching from metreleptin as Completed; the study assessed safety in patients who had been stable on metreleptin for at least six months.
Why it matters
If mibavademab demonstrates an acceptable safety profile in metreleptin-experienced patients, it could offer a subcutaneous antibody alternative to the more complex metreleptin regimen, potentially expanding the treatable GLD population and supporting a BLA submission.
Analysis
Regeneron's investment in mibavademab for GLD targets a rare disease with a very small patient population, but successful data would add a regulatory asset and demonstrate the company's leptin receptor biology platform has clinical utility beyond the index indication. The switch-study design is pragmatically important because most GLD patients in practice are already on metreleptin.
What to watch
Watch for Regeneron to disclose mibavademab safety and metabolic control data from this Phase 3 and to announce a BLA submission timeline, likely in 2026 or early 2027.
Roche's higher-dose ocrelizumab Phase 3 in primary progressive MS remains active but not recruiting
ClinicalTrials.gov lists the Phase 3 study (NCT04548999) evaluating a higher intravenous dose of ocrelizumab every 24 weeks versus the approved dose in primary progressive multiple sclerosis as Active, Not Recruiting — meaning enrollment is complete and follow-up is ongoing.
Why it matters
Demonstrating that higher-dose ocrelizumab provides incremental slowing of disability progression in PPMS — one of the most treatment-resistant neurological conditions — would be clinically meaningful and could support a label update extending dosing intervals or increasing dose intensity.
Analysis
Roche has a dominant position in PPMS with ocrelizumab, and this dose-optimization study is a lifecycle management play that could reinforce the franchise against emerging competition from fenebrutinib and other BTK inhibitors in development for progressive MS. The outcome will matter more for label differentiation than for new patient capture.
What to watch
Watch for Roche to report primary endpoint data — likely 12- or 24-week confirmed disability progression — from this study at ECTRIMS 2026 or 2027, which will inform whether a higher-dose regimen enters regulatory review.
Oral GLP-1 competing directly with Lilly and Novo. Best-in-class efficacy in Phase 2 at ~15% weight loss. Phase 3 success could make Viking an M&A target.
No coverage today
None of your tracked companies appeared in today's sources.